Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial

Abstract Background and aims Cardiovascular outcome trials have documented a strong benefit of sodium glucose cotransporter-2 inhibitors (SGLT2i) on the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D) with or without established cardiovascular disease or prior h...

Full description

Bibliographic Details
Main Authors: Benedetta Maria Bonora, Saula Vigili de Kreutzenberg, Angelo Avogaro, Gian Paolo Fadini
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Sodium glucose cotransporter-2 inhibitor
Dapagliflozin
Heart failure
Impedance cardiography
Online Access:http://link.springer.com/article/10.1186/s12933-019-0910-5

Internet

http://link.springer.com/article/10.1186/s12933-019-0910-5

Similar Items